Tilsotolimod clinical trials
Also written IMO-2125.
How each study uses tilsotolimod is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tilsotolimod studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
9 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 2
Idera Pharmaceuticals, Inc. (6) · AbbVie (1) · A.J.M. van den Eertwegh (1) · Gustave Roussy, Cancer Campus, Grand Paris (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses tilsotolimod is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 MelanomaRecruitingPhase 2A.J.M. van den EertweghNCT04126876Written as Tilsotolimod
- Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced CancersTerminatedPhase 1Gustave Roussy, Cancer Campus, Grand ParisNCT04270864Written as Tilsotolimod
- A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaCompletedPhase 1AbbVieNCT04196283Written as Tilsotolimod
- A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory MelanomaTerminatedPhase 3Idera Pharmaceuticals, Inc.NCT03445533Written as Tilsotolimod with Ipilimumab
- A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic MelanomaCompletedPhase 2Idera Pharmaceuticals, Inc.NCT02644967Written as IMO-2125
- Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)Active, not recruitingPhase 2Idera Pharmaceuticals, Inc.NCT03865082Written as Tilsotolimod
- A Study of Intratumoral IMO-2125 in Patients With Refractory Solid TumorsCompletedPhase 1Idera Pharmaceuticals, Inc.NCT03052205Written as IMO-2125
- Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 PatientsCompletedPhase 1Idera Pharmaceuticals, Inc.NCT00990938Written as IMO-2125
- Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected PatientsCompletedPhase 1Idera Pharmaceuticals, Inc.NCT00728936Written as IMO-2125
Codes
What other systems call tilsotolimod · ClinicalTrials.gg INT001921
- UNII (FDA) G287IC9MH3TILSOTOLIMODOne source FDA
- NCI Thesaurus C152632TilsotolimodOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | G287IC9MH3 | TILSOTOLIMOD | One source FDA |
| NCI Thesaurus | C152632 | Tilsotolimod | One source FDA |
Also registered as tilsotolimod sodium (UNII I6CNU8SY0F).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.